These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32859648)

  • 1. A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality.
    McManus D; Naughton BD
    BMJ Glob Health; 2020 Aug; 5(8):. PubMed ID: 32859648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review.
    Asrade Mekonnen B; Getie Yizengaw M; Chanie Worku M
    J Pharm Policy Pract; 2024; 17(1):2375267. PubMed ID: 39015754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substandard and falsified medicines in African pharmaceutical markets: A case study from Ethiopia.
    Mengesha A; Bastiaens H; Ravinetto R; Gibson L; Dingwall R
    Soc Sci Med; 2024 May; 349():116882. PubMed ID: 38669893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The quality of veterinary medicines and their implications for One Health.
    Vidhamaly V; Bellingham K; Newton PN; Caillet C
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35918072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country.
    Khurelbat D; Dorj G; Sunderland B; Sanjjav T; Bayarsaikhan E; Damdinjav D; Dorj G; Jigjidsuren A; Lkhagvasuren O; Erdenetsetseg B
    BMC Public Health; 2020 May; 20(1):743. PubMed ID: 32434489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines.
    Akpobolokemi T; Martinez-Nunez RT; Raimi-Abraham BT
    J Med Access; 2022; 6():23992026211070406. PubMed ID: 36204519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor-Quality Medicines in Cameroon: A Critical Review.
    Waffo Tchounga CA; Sacré PY; Ciza Hamuli P; Ngono Mballa R; Nnanga Nga E; Hubert P; Marini Djang'eing'a R
    Am J Trop Med Hyg; 2021 Jun; 105(2):284-294. PubMed ID: 34125703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review.
    Sorato MM; Davari M; Kebriaeezadeh A
    J Med Access; 2024; 8():27550834241236598. PubMed ID: 38476401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing Medicine Quality by Active Pharmaceutical Ingredient Levels: A Systematic Review and Meta-Analysis across Low- and Middle-Income Countries.
    Ozawa S; Chen HH; Lee YA; Higgins CR; Yemeke TT
    Am J Trop Med Hyg; 2022 Jun; 106(6):1778-1790. PubMed ID: 35895431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries.
    Hauk C; Hagen N; Heide L
    Am J Trop Med Hyg; 2021 Mar; 104(5):1936-1945. PubMed ID: 33788775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches.
    Ozawa S; Higgins CR; Nwokike JI; Phanouvong S
    Am J Trop Med Hyg; 2022 Jul; 107(1):14-20. PubMed ID: 35895357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substandard and counterfeit medicines: a systematic review of the literature.
    Almuzaini T; Choonara I; Sammons H
    BMJ Open; 2013 Aug; 3(8):e002923. PubMed ID: 23955188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of community pharmacists' readiness to implement the Falsified Medicines Directive (Directive 2011/62/EC): an English cross-sectional survey with geospatial analysis.
    Barrett R
    BMJ Open; 2020 Jan; 10(1):e033405. PubMed ID: 31924640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
    Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
    Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor-quality antimalarials further health inequities in Uganda.
    Evans DR; Higgins CR; Laing SK; Awor P; Ozawa S
    Health Policy Plan; 2019 Dec; 34(Supplement_3):iii36-iii47. PubMed ID: 31816072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.